IGSF11 (immunoglobulin superfamily member 11) functions as a cell adhesion molecule that promotes cancer progression through multiple mechanisms. As a transmembrane protein with immunoglobulin-like domains, IGSF11 mediates cell-cell adhesion through homophilic interactions 1. The protein is frequently upregulated in various cancers, including glioblastoma, melanoma, gastric cancer, and breast cancer 231. IGSF11 promotes malignant phenotypes by forming complexes with signaling molecules such as RAP1, specifically through its L372-R378 region, which drives melanoma cell migration and invasion 2. Additionally, IGSF11 serves as an inhibitory immune checkpoint ligand that binds to VISTA receptor, suppressing T cell function and creating an immunosuppressive tumor microenvironment 345. In gliomas, high IGSF11 expression correlates with advanced tumor grade and poor prognosis 3. Therapeutic targeting of IGSF11 shows promise, as silencing reduces melanoma cell proliferation and migration while promoting anti-tumor T cell cytokine profiles 6. The IGSF11-VISTA axis represents a critical immune checkpoint pathway, particularly in brain tumors where targeting this interaction provides survival benefits through activation of brain-resident microglia 4.